Galderma receives EU approval for new treatment for lateral canthal lines

Galderma has announced that Azzalure, its new treatment for lateral canthal lines, has been approved in several European countries.

The product, which is in-licensed from Ipsen, is designed for the treatment of lateral canthal lines – also known as crow's feet – either alone or in combination with glabellar line treatments.

Phase III studies have shown that Azzalure injections significantly reduced the severity of lateral canthal lines compared with placebo, resulting in significant patient satisfaction, including when the product was offered alongside a glabellar line treatment.

Azzalure received a positive opinion from the French regulatory authority ANSM in November 2016, with national approvals having now been issued by the UK, Ireland, Germany and Austria.

The remaining EU member states are due to issue similar national licence approvals in the coming weeks.

Alexandre Brennan, vice-president of aesthetic and corrective business at Galderma, said: "This enables Galderma to provide healthcare practitioners with scientific support and medical education, and with the appropriate license to be able to promote and demonstrate a good safety profile, clinical effect and patient satisfaction."

With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.